A Phase I Study of KTX-1001, an Oral, First-In-Class, Selective, and Potent MMSET Catalytic Inhibitor that Suppresses H3K36me2 in Patients with Relapsed and Refractory Multiple Myeloma

Brief Summary

Type:
Multiple Myeloma

Study Type:
Treatment

Phase:
I

ClinicalTrials.gov Identifier:
NCT05651932

Study #:
STUDY00150138

Start Date:
Oct 23, 2023

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05651932

View Complete Trial Details & Eligibility at ClinicalTrials.gov